65. Primary immunodeficiency Clinical trials / Disease details


Clinical trials : 482 Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-015739-34-DE
(EUCTR)
09/12/200914/09/2009Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT)Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT) This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT)Trade Name: Catapresan 75, Tabletten
INN or Proposed INN: Clonidinhydrochlorid
Trade Name: L-Arginin-hydrochlorid-einmolar Fresenius
INN or Proposed INN: Argininhydrochlorid
Trade Name: Progynova 21 mite
INN or Proposed INN: Estradiolvalerat
Trade Name: NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung
INN or Proposed INN: Somatotropin
Goethe-Universität Frankfurt/MainNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany